Dimethyl diotadecyl ammonium bromide as adjuvant for delayed hypersensitivity in mice

Area of Science:

• Immunology
• Vaccine Adjuvants
• Cellular Immunity

Background:

• Adjuvants are crucial for enhancing vaccine efficacy.
• Freund's Complete Adjuvant (FCA) is a common adjuvant, but its limitations are being explored.
• Cationic lipids like dimethyl dioctadecyl ammonium bromide (DDA) are investigated as alternative adjuvants.

Purpose of the Study:

• To evaluate the efficacy of dimethyl dioctadecyl ammonium bromide (DDA) as an adjuvant for inducing delayed type hypersensitivity (DH).
• To compare the immune response generated by DDA with that of Freund's Complete Adjuvant (FCA).
• To determine the specificity of the DH response induced by DDA.

Main Methods:

• Mice were immunized with antigens (sheep red blood cells or DNP28-BSA) formulated with DDA or FCA.
• Delayed type hypersensitivity was measured by footpad swelling.
• Cyclophosphamide (CY) treatment was used to analyze the kinetics of the immune response.
• Epitope density variations and homologous/heterologous antigen challenges assessed specificity.

Main Results:

• DDA significantly enhanced DH responses compared to FCA.
• DDA-adjuvanted antigen elicited faster and higher peak immune responses than FCA.
• The DH response was confirmed to be DNP-specific.
• Cyclophosphamide treatment delayed the onset of swelling and eliminated adjuvant-specific differences.

Conclusions:

• Dimethyl dioctadecyl ammonium bromide (DDA) is a potent adjuvant for inducing delayed type hypersensitivity (DH).
• DDA offers advantages over Freund's Complete Adjuvant (FCA) in terms of response magnitude and kinetics.
• DDA-adjuvanted vaccines hold promise for developing more effective immunotherapies.